Your browser doesn't support javascript.
loading
EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
Agache, Ioana; Akdis, Cezmi A; Akdis, Mubeccel; Brockow, Knut; Chivato, Tomas; Del Giacco, Stefano; Eiwegger, Thomas; Eyerich, Kilian; Giménez-Arnau, Ana; Gutermuth, Jan; Guttman-Yassky, Emma; Maurer, Marcus; Ogg, Graham; Ong, Peck Y; O'Mahony, Liam; Schwarze, Jürgen; Warner, Amena; Werfel, Thomas; Palomares, Oscar; Jutel, Marek.
Afiliación
  • Agache I; Faculty of Medicine, Transylvania University, Brasov, Romania.
  • Akdis CA; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Akdis M; Christine-Kühne-Center for Allergy Research and Education (CK-CARE, Davos, Switzerland.
  • Brockow K; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
  • Chivato T; Department of Dermatology and Allergology Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
  • Del Giacco S; School of Medicine, University CEU San Pablo, Madrid, Spain.
  • Eiwegger T; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Eyerich K; Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
  • Giménez-Arnau A; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Gutermuth J; Karl Landsteiner University of Health Sciences, Krems, Austria.
  • Guttman-Yassky E; Department of Paediatrics, University Hospital St. Pölten, Pölten, Austria.
  • Maurer M; Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.
  • Ogg G; Department of Dermatology, Hospital del Mar- Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Ong PY; Department of Dermatology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB, Brussels, Belgium.
  • O'Mahony L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Schwarze J; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Warner A; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Werfel T; Division of Clinical Immunology & Allergy, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Palomares O; Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
  • Jutel M; Centre for Inflammation Research, Child Life and Health, The University of Edinburgh, Edinburgh, UK.
Allergy ; 77(1): 17-38, 2022 01.
Article en En | MEDLINE | ID: mdl-34324716
ABSTRACT
Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Urticaria / Productos Biológicos / Antialérgicos / Urticaria Crónica Tipo de estudio: Guideline Límite: Adolescent / Adult / Child / Humans Idioma: En Revista: Allergy Año: 2022 Tipo del documento: Article País de afiliación: Rumanía
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Urticaria / Productos Biológicos / Antialérgicos / Urticaria Crónica Tipo de estudio: Guideline Límite: Adolescent / Adult / Child / Humans Idioma: En Revista: Allergy Año: 2022 Tipo del documento: Article País de afiliación: Rumanía